江西济民可信集团有限公司

About 江西济民可信集团有限公司

Founded in 1999, with a pharmaceutical history dating back to the 1950s, Ji Min Ke Xin now employs over 12,000 people. Headquartered in Nanchang, China, the group operates industrial platforms and R&D institutions across Jiangxi, Beijing, Shanghai, Jiangsu, and Zhejiang. In 2017, the group's operating income exceeded 23.7 billion yuan, ranking 6th among China's top 100 pharmaceutical manufacturers and 10th among China's top 100 pharmaceutical industry companies. Adhering to a strategy of innovation-driven development, the company focuses on the R&D, production, and sales of modern traditional Chinese medicine, chemical drugs, biological preparations, and health products. It boasts 7 pharmaceutical bases, 1 international postdoctoral workstation, 1 national-level laboratory accredited by CNAS, and 2 provincial-level engineering technology centers, with an overseas drug R&D team. Currently, the group has achieved significant results in the fields of cardiovascular and cerebrovascular diseases, nephrology, oncology, anti-infection, and emergency drugs. Core products such as "Jin Shui Bao," "Xing Nao Jing," "Kang Lai Te," "Xi Neng," "Li Xing," "Huang Shi Xiang Sheng Wan," and "Jiu Hua Zhi Chuang Shuan" hold significant market share in their respective categories nationwide. Ji Min Ke Xin consistently upholds its mission of "Serving the people and being trustworthy to the world," actively participating in social welfare and charitable causes, with cumulative donations totaling 317 million yuan and receiving the "China Charity Outstanding Contribution Award" from the China Charity Federation. Looking ahead, Ji Min Ke Xin will continue to provide trustworthy pharmaceutical products and medical services, striving to improve human health and quality of life.